Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20 mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.

Detailed Description
-----------------
This study aims to compare the absorption and disposition kinetics of two products containing rosuvastatin under fasting conditions. These products are: Rosuvastatin/ Verisfield 20 mg film-coated tablets, a Test product manufactured by HELP S.A., Greece and Crestor™/ AstraZeneca 20 mg film-coated tablets, a Reference product manufactured by AstraZeneca, UK. The bioequivalence of a single 20 mg dose of both products will be assessed by comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles for rosuvastatin.

Official Title
-----------------
A Pivotal, Open-label, Balanced, Randomised, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Single Oral Dose Bioequivalence Study of Rosuvastatin/ Verisfield 20 mg Film-coated Tablets Versus Crestor/ AstraZeneca 20 mg Film-coated Tablets in Healthy Adults Under Fasting Conditions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Rosuvastatin 20 mg film-coated tablets
* Drug: Crestor 20 mg film-coated tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willingness to provide informed consent to participate in the study. Comprehension of the nature and purpose of the study and willingness to comply with the requirements of the entire procedure. Healthy adult, human Indian volunteers within the age range of 18 to 45 years (both inclusive). Body Mass Index (BMI) ≥ 18.50 kg/m2 to ≤ 30.00 kg/m2. Hemoglobin: ≥12.0 gm% for male and ≥11.5 gm% for female. Absence of disease markers of HIV I & II, HBsAg, HCVAb and P24 antigen test. Females of childbearing age must be practicing an acceptable form of birth control for at least six months before screening, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy. Females of childbearing age agree to use acceptable form of birth control during the study and until the drug is washed out from the body, i.e. at least 14 days after last dosing, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy. Absence of significant disease or clinically significant abnormal laboratory values during the laboratory evaluations. Absence of any diseases in medical history or physical examination during the screening. Have a normal 12-lead ECG or one with abnormality considered clinically insignificant. Have a normal chest X-ray (P. A. view). Non smokers (since last six months) Negative serum β-HCG at the time of screening (for females only) Exclusion Criteria: History / evidence of allergy or hypersensitivity to rosuvastatin or to any of the excipients or to any other drug. Any major illness within the last three months or any significant ongoing chronic medical illness. History of or active liver or kidney disease. History of or active deep vein thrombosis and thromboembolic disorders. History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia, endometriosis and undiagnosed vaginal bleeding (for females only). History of drug abuse (including barbiturates, benzodiazepines, opioids, cocaine, cannabinoids and amphetamine etc.) within the last three months. History of neuropsychiatric diseases. History of hypothyroidism. Personal or family history of hereditary muscular disorders. History of myopathy. History of myalgia. History of rhabdomyolysis. History of alcohol abuse. History of proteinuria. Asian population (except Indian). History of interstitial lung disease. History of or current gastro-intestinal diseases influencing drug absorption. History of alcoholism (more than two years), moderate drinkers (more than three drinks per day). Participation in any clinical trial within last three months. History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm. Donation of blood (one unit or 350 mL or more) within last three months. Use of any prescription drug therapy within last two weeks and over the counter (OTC) drugs or herbal products within last one week. Pregnant women. Breast feeding women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test Product<br>Rosuvastatin 20 mg film-coated tablets | Drug: Rosuvastatin 20 mg film-coated tablets<br>* Single oral dose of 20 mg<br>|
| Active Comparator: Reference product<br>Crestor 20 mg film-coated tablets | Drug: Crestor 20 mg film-coated tablets<br>* Single oral dose of 20 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the plasma concentration (AUC0-t) from zero (0) hours to time (t) | The area under the plasma concentration versus time curve, from time zero (0) to t hours | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 
| Maximum concentration (Cmax) | Maximum measured plasma concentration | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to maximum concentration (Tmax) | Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 
| Elimination rate constant (Kel) | Apparent first-order elimination or terminal rate constant | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 
| Terminal half life (t1/2) | The elimination or terminal half-life | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 
| Area under the plasma concentration (AUC0-infinity) from zero (0) hours to infinity | The area under the plasma concentration versus time curve from time (0) to infinity | Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose | 
| Number of participants with Adverse Events |  | 6 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bioequivalence, two rosuvastatin-containing products